PROTAC ATR degrader-2 - HY-161615
Nur noch %1 verfügbar
Catalog #
HY-161615
Ab
579,00 €
PROTAC ATR degrader-2 (Compound 8i) is a PROTAC degrader for ATR, through of . PROTAC ATR degrader-2 degrades ATR in acute myeloid leukemia (AML) cells MV-4-11 and MOLM-13, with DC50 of 22.9 and 34.5 nM. APROTAC ATR degrader-2 induces apoptosis, inhibits proliferations of AML cells. PROTAC ATR degrader-2 exhibits good pharmacokinetics charachers and antitumor efficacy against AML in mouse model. (Pink: ATR ligand (HY-161616); Blue:E3 ligase ligand Lenalidomide (HY-A0003); Black: linker)[1]
| Datasheet URL | http://file.medchemexpress.com/batch_PDF/HY-161615/PROTAC-ATR-degrader-2-DataSheet-MedChemExpress.pdf |
|---|---|
| Shipping | Room Temperature |
| Application | Cancer-programmed cell death |
| CAS | 3010273-12-5 |
| Storage | -20°C, 3 years; 4°C, 2 years (Powder) |
| MWT | 743.81 |
| Solubility | DMSO : 100 mg/mL (ultrasonic) |
| Clinical Information | No Development Reported |
| Target | Apoptosis;PROTACs |
| Application: | Cancer-programmed cell death |
|---|